EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Recommendation of “Buy” from Analysts

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) have earned a consensus rating of “Buy” from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $26.63.

EYPT has been the topic of several research analyst reports. Chardan Capital restated a “buy” rating and set a $33.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a “sell” rating in a report on Friday, March 14th. Citigroup initiated coverage on shares of EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $33.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th.

EyePoint Pharmaceuticals Stock Up 3.9 %

EYPT opened at $5.90 on Tuesday. The stock has a market cap of $405.50 million, a P/E ratio of -2.95 and a beta of 1.39. EyePoint Pharmaceuticals has a 12 month low of $3.91 and a 12 month high of $21.26. The company has a fifty day simple moving average of $5.92 and a 200 day simple moving average of $7.80.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.10). The business had revenue of $11.60 million during the quarter, compared to analyst estimates of $11.02 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. On average, equities research analysts expect that EyePoint Pharmaceuticals will post -2.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Cyndeo Wealth Partners LLC raised its position in EyePoint Pharmaceuticals by 48.6% during the first quarter. Cyndeo Wealth Partners LLC now owns 25,250 shares of the company’s stock worth $137,000 after acquiring an additional 8,260 shares in the last quarter. Principia Wealth Advisory LLC raised its holdings in shares of EyePoint Pharmaceuticals by 97.4% in the 1st quarter. Principia Wealth Advisory LLC now owns 533,778 shares of the company’s stock valued at $2,893,000 after purchasing an additional 263,396 shares during the period. GAMMA Investing LLC lifted its stake in EyePoint Pharmaceuticals by 3,174.4% in the 1st quarter. GAMMA Investing LLC now owns 10,249 shares of the company’s stock valued at $56,000 after purchasing an additional 9,936 shares during the last quarter. Wellington Management Group LLP grew its holdings in EyePoint Pharmaceuticals by 3.2% during the fourth quarter. Wellington Management Group LLP now owns 177,316 shares of the company’s stock worth $1,321,000 after purchasing an additional 5,552 shares during the period. Finally, California State Teachers Retirement System increased its position in EyePoint Pharmaceuticals by 3.8% during the fourth quarter. California State Teachers Retirement System now owns 48,614 shares of the company’s stock worth $362,000 after buying an additional 1,797 shares during the last quarter. Institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.